<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02848001</url>
  </required_header>
  <id_info>
    <org_study_id>CC-90009-AML-001</org_study_id>
    <secondary_id>2017-001535-39</secondary_id>
    <nct_id>NCT02848001</nct_id>
  </id_info>
  <brief_title>A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes</brief_title>
  <official_title>A Phase 1, Open-label, Dose Finding Study of CC-90009, a Novel Cereblon E3 Ligase Modulating Drug, in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects
      with relapsed or refractory acute myeloid leukemia and relapsed or refractory high-risk
      myelodysplastic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study CC-90009-AML-001 is an open-label, Phase 1, dose escalation and expansion,
      first-in-human clinical study of CC-90009 in subjects with relapsed or refractory acute
      myeloid leukemia (AML) and relapsed or refractory high-risk myelodysplastic syndrome.

      The dose escalation part (Part A) of the study will evaluate the safety and tolerability of
      escalating doses of CC-90009 in relapsed and refractory AML. The expansion part, (Part B),
      will further evaluate the safety and efficacy of CC-90009 administered at or below the
      maximum tolerated dose (MTD) in selected expansion cohorts of one or more dosing regimens in
      order to determine the recommended Phase 2 dose (RP2D) for subjects with relapsed or
      refractory AML and relapsed or refractory high-risk myelodysplastic syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2016</start_date>
  <completion_date type="Anticipated">February 26, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 25, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose- limiting toxicity (DLT)</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Number of participants with a DLT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-tolerated dose (NTD)</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Dose level at which 2 or more of up to 6 evaluable subjects in any dose cohort experience a DLT in Cycle 1 during dose escalation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Last dose level(s) below the NTD with 0 or 1 out of 6 evaluable subjects experiencing a DLT in Cycle 1 during dose escalation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-Cmax</measure>
    <time_frame>Up to Day 11</time_frame>
    <description>Maximum observed concentration in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUC24</measure>
    <time_frame>Up to Day 11</time_frame>
    <description>Area under the plasma concentration time-curve from time 0 to 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - tmax</measure>
    <time_frame>Up to Day 11</time_frame>
    <description>Time to peak (maximum) plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - t 1/2</measure>
    <time_frame>Up to Day 11</time_frame>
    <description>terminal half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - CL</measure>
    <time_frame>Up to Day 11</time_frame>
    <description>Total body clearance of the drug from plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Vss</measure>
    <time_frame>Up to Day 11</time_frame>
    <description>Volume of distribution at steady-state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy of CC-90009</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Determined by acute myeloid leukemia (AML) response rate based on the International Working Group (IWG) Response Criteria in AML (Cheson, 2003)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy of CC-90009 - AML</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Determined by acute myeloid leukemia (AML) response rate based on the International Working Group (IWG) Response Criteria in AML.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy of CC-90009 - MDS</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Determined by myelodysplastic syndrome (MDS) response rate based on the International Working Group (IWG) response criteria for Myelodysplasia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>CC-90009 - Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will be administered intravenously per dosing schedule in a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-90009 - Part B - AML and MDS patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Relapsed or refractory AML and MDS subjects. IP will be administered intravenously per dosing schedule determined in Part A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-90009</intervention_name>
    <description>CC-90009</description>
    <arm_group_label>CC-90009 - Part A</arm_group_label>
    <arm_group_label>CC-90009 - Part B - AML and MDS patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women ≥ 18 years of age, at the time of signing the ICD (Informed Consent
             Document).

          2. Subject must understand and voluntarily sign an ICD prior to any study-related
             assessments/procedures being conducted.

          3. Relapsed or refractory AML (Acute Myeloid Leukemia) (Parts A and B) or relapsed or
             refractory high-risk MDS (Myelodysplastic Syndrome) (Part B only) as defined by World
             Health Organization criteria who are not suitable for other established therapies.

          4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2.

          5. At least 4 weeks (from first dose) has elapsed from donor lymphocyte infusion (DLI)
             without conditioning.

          6. Subjects must have the following screening laboratory values:

               -  Total White Blood Cell count (WBC) &lt; 25 x 109/L prior to first infusion. Prior or
                  concurrent treatment with hydroxyurea to achieve this level is allowed.

               -  Selected electrolytes within normal limits or correctable with supplements.

               -  Serum bilirubin ≤ 1.5 x ULN (upper limit of normal).

               -  Estimated serum creatinine clearance of ≥ 60 mL/min using the Cockcroft-Gault
                  equation.

          7. Agree to follow the CC-90009 Pregnancy Prevention Plan (PPP)

        Exclusion Criteria:

          1. Subjects with acute promyelocytic leukemia (APL)

          2. Subjects with clinical symptoms suggesting active central nervous system (CNS)
             leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid is only required if
             there is clinical suspicion of CNS involvement by leukemia during screening.

          3. Patients with prior autologous hematopoietic stem cell transplant who, in the
             investigator's judgment, have not fully recovered from the effects of the last
             transplant (e.g., transplant related side effects).

          4. Prior allogeneic hematopoietic stem cell transplant (HSCT) with either standard or
             reduced intensity conditioning ≤ 6 months prior to starting CC-90009.

          5. Subjects on systemic immunosuppressive therapy post HSCT at the time of screening, or
             with clinically significant graft-versus-host disease (GVHD). The use of topical
             steroids for ongoing skin or ocular GVHD is permitted.

          6. Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives
             or 4 weeks prior to starting CC-90009, whichever is shorter. Hydroxyurea is allowed to
             control peripheral leukemia blasts.

          7. Leukapheresis ≤ 2 weeks prior to starting CC-90009.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Pourdehnad, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Associate Director Clinical Trial Disclosure</last_name>
    <phone>1-888-260-1599</phone>
    <email>clinicaltrialdisclosure@celgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University Siteman Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille Cedex 9</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy Faculte de Medecine Paris Sud Service de pneumologie</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spedali Civili Di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedale Ca Granda - Niguarda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>N-5053</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital, Rikshospitalet HF</name>
      <address>
        <city>Oslo</city>
        <zip>N-0027</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H Clinic I Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosptial La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>0X3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 22, 2016</study_first_submitted>
  <study_first_submitted_qc>July 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2016</study_first_posted>
  <last_update_submitted>December 2, 2019</last_update_submitted>
  <last_update_submitted_qc>December 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CC-90009</keyword>
  <keyword>Hematologic Cancers</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>AML</keyword>
  <keyword>MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

